NCT01904526View on ClinicalTrials.gov

PK/PD Comparison of Guanfacine ER and IR

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Smoking
Interventions
DRUG

Guanfacine

3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.

Trial Locations (1)

06519

Yale Center for Clinical Investigations, Yale University, New Haven

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Yale University

OTHER

NCT01904526 - PK/PD Comparison of Guanfacine ER and IR | Biotech Hunter | Biotech Hunter